GC Genome Corporation (KOSDAQ:340450)
South Korea
· Delayed Price · Currency is KRW 7,880.00
-30.00 (-0.38%)
Aug 14, 2025, 3:30 PM KST
GC Genome Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 26,950 | 25,888 | 27,292 | 24,114 | 18,498 | 13,556 | Upgrade
|
| Other Revenue | - | - | - | - | -0 | - | Upgrade
|
| Revenue | 26,950 | 25,888 | 27,292 | 24,114 | 18,498 | 13,556 | Upgrade
|
| Revenue Growth (YoY) | 45.69% | -5.15% | 13.18% | 30.36% | 36.46% | 11.51% | Upgrade
|
| Cost of Revenue | 14,769 | 14,181 | 13,595 | 13,349 | 11,318 | 7,457 | Upgrade
|
| Gross Profit | 12,180 | 11,707 | 13,697 | 10,765 | 7,180 | 6,099 | Upgrade
|
| Selling, General & Admin | 6,205 | 6,464 | 5,791 | 5,564 | 4,204 | 2,996 | Upgrade
|
| Research & Development | 6,004 | 6,053 | 7,355 | 8,121 | 4,841 | 2,948 | Upgrade
|
| Other Operating Expenses | 50.9 | 54.31 | 46.41 | 47.85 | 17.65 | 18.08 | Upgrade
|
| Operating Expenses | 12,641 | 12,940 | 13,537 | 14,000 | 9,289 | 6,102 | Upgrade
|
| Operating Income | -461 | -1,234 | 160.08 | -3,236 | -2,109 | -2.73 | Upgrade
|
| Interest Expense | -756.78 | -959.77 | -920.67 | -1,695 | -1,482 | -119.99 | Upgrade
|
| Interest & Investment Income | 1,150 | 1,059 | 482.41 | 508.99 | 297 | 40.74 | Upgrade
|
| Currency Exchange Gain (Loss) | 597.68 | 882.39 | -83.19 | -160.36 | -12.42 | 2.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 235.69 | 248.44 | -454.79 | 756.59 | 3,727 | 42.54 | Upgrade
|
| EBT Excluding Unusual Items | 765.84 | -3.2 | -816.17 | -3,826 | 420.4 | -37.18 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -2.93 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.36 | 1.37 | 1.57 | -44.89 | -13.83 | -0.29 | Upgrade
|
| Asset Writedown | -1,125 | -1,125 | - | - | - | - | Upgrade
|
| Pretax Income | -358.04 | -1,127 | -814.6 | -3,874 | 406.57 | -37.47 | Upgrade
|
| Income Tax Expense | -25.38 | 129.84 | -264.5 | -110.52 | 113.37 | -34.8 | Upgrade
|
| Net Income | -332.67 | -1,257 | -550.1 | -3,763 | 293.2 | -2.67 | Upgrade
|
| Net Income to Common | -332.67 | -1,257 | -550.1 | -3,763 | 293.2 | -2.67 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 18 | 18 | 16 | 16 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 18 | 18 | 16 | 16 | 18 | Upgrade
|
| Shares Change (YoY) | 16.78% | -0.66% | 13.53% | 0.97% | -10.25% | 90.88% | Upgrade
|
| EPS (Basic) | -17.81 | -69.00 | -30.00 | -233.00 | 18.33 | -0.15 | Upgrade
|
| EPS (Diluted) | -17.81 | -69.00 | -30.00 | -233.00 | 18.33 | -0.15 | Upgrade
|
| Free Cash Flow | 2,619 | 49.4 | -4,065 | -5,639 | -2,935 | -1,747 | Upgrade
|
| Free Cash Flow Per Share | 140.20 | 2.71 | -221.71 | -349.17 | -183.51 | -98.03 | Upgrade
|
| Gross Margin | 45.20% | 45.22% | 50.19% | 44.64% | 38.81% | 44.99% | Upgrade
|
| Operating Margin | -1.71% | -4.76% | 0.59% | -13.42% | -11.40% | -0.02% | Upgrade
|
| Profit Margin | -1.23% | -4.86% | -2.02% | -15.61% | 1.58% | -0.02% | Upgrade
|
| Free Cash Flow Margin | 9.72% | 0.19% | -14.90% | -23.39% | -15.87% | -12.89% | Upgrade
|
| EBITDA | 2,673 | 1,986 | 3,701 | -429 | -51.89 | 978.26 | Upgrade
|
| EBITDA Margin | 9.92% | 7.67% | 13.56% | -1.78% | -0.28% | 7.22% | Upgrade
|
| D&A For EBITDA | 3,134 | 3,219 | 3,541 | 2,807 | 2,057 | 980.99 | Upgrade
|
| EBIT | -461 | -1,234 | 160.08 | -3,236 | -2,109 | -2.73 | Upgrade
|
| EBIT Margin | -1.71% | -4.76% | 0.59% | -13.42% | -11.40% | -0.02% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 27.88% | - | Upgrade
|
| Advertising Expenses | - | 90.12 | 143.22 | 148.84 | 97.65 | 94.14 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.